J&J's Gorsky says military service shaped his leadership style by Kyle Blankenship Friday, April 19, 2019 What does it take to run one of pharma’s biggest whales? As J&J CEO Alex Gorsky told Fortune, six years in the U.S. Army made all the difference.
Teva CEO nabs whopping $33M in first full year on the job by Carly Helfand Wednesday, April 17, 2019 If you thought Teva went big-time with CEO Kåre Schultz's 2017 pay package, check out his 2018 numbers—especially his $20 million cash bonus.
Daiichi, Keytruda, Chi-Med and more—FiercePharmaAsia by Angus Liu Friday, April 5, 2019 Daiichi inks $6.9 billion ADC deal with AZ, appoints new CEO; Keytruda nabs first-line lung cancer nod in China.
Daiichi unveils CEO successor amid oncology refocus by Angus Liu Friday, March 29, 2019 Daiichi is transitioning from CV and metabolic diseases to oncology, and it says now is the right time for a new CEO to take the helm.
Sanofi eyes successors for CEO Olivier Brandicourt by Eric Sagonowsky Monday, March 18, 2019 Sanofi is working on a succession plan for CEO Olivier Brandicourt, who'll hit mandatory retirement age in 2021.
What do Allergan activists really want? A new CEO, analyst says by Carly Helfand Tuesday, March 5, 2019 Activists have been pushing for a split of Allergan's CEO and chairman’s roles. But the campaign may be about more than just the split.
Another Allergan activist backs immediate split to CEO, chairman by Eric Sagonowsky Friday, March 1, 2019 Allergan has faced pressure to split Brent Saunders' CEO and chairman jobs, and now rebel investors are teaming up.
Ironwood swipes AZ commercial hotshot Mallon for its next CEO by Carly Helfand Sunday, January 6, 2019 The first week of 2019 looks a lot like 2018 in at least one regard: A Big Pharma company’s commercial head is on the move.
New Pfizer CEO's top priorities? Think China and pipeline by Carly Helfand Tuesday, December 18, 2018 Wondering how much incoming Pfizer CEO Albert Bourla is going to shake things up at the drugmaker? Not much, apparently.
Gilead swipes Roche pharma chief O'Day for CEO by Carly Helfand Monday, December 10, 2018 With Gilead’s CEO on the way out and revenues tumbling, the company needs a leader who can pump up cancer sales. And it may have found just that.
